Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma

NCT06170151 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.

NCT NCT06170151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06170151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma
Lead sponsor
IRCCS San Raffaele
Phase
Observational
Overall status
Completed
Start date
May 24, 2021
Completion date
December 1, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma